Skip to content

Efficacy and Cytokine Alteration of Repeated High-voltage Long-duration Pulse Radiofrequency Therapy for Zoster-Associated Pain

Efficacy and Cytokine Alteration of Repeated High-voltage Long-duration Pulse Radiofrequency Therapy for Zoster-Associated Pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116977
Enrollment
Unknown
Registered
2026-01-18
Start date
2024-12-02
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zoster-associated pain

Interventions

Sponsors

The second hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The subjects were all hospitalized patients in our hospital; 2.Determine the previous history of herpes zoster, involving the neck, chest and lumbar ganglia, and conform to group A (acute phase of herpes zoster): from the onset of herpes zoster, the appearance of rash to the healing of skin lesions, the pain lasts for 1 month (the number of days from the onset of herpes zoster to the implementation of PRF = 1 month); Group B (postherpetic neuralgia): the diagnostic criteria of pain lasting for 1 month or more (the number of days between the onset of herpes zoster and the implementation of PRF>1 month) from the onset of herpes zoster, the appearance of rash to the healing of skin lesions; 3.Pain score (such as VAS score) >= 4 points; 4.Aged 50-80 years old, without severe heart, lung, liver, kidney and other organic diseases; 5.No psychosis or cognitive impairment; 6.Understand the various intervention measures in the experiment, and voluntarily participate in the experimental study; 7.There was no abnormality in MRI or X-ray examination of the spine at the corresponding lesion segment;

Exclusion criteria

Exclusion criteria: 1.The puncture site has infection, abnormal coagulation function, allergy to local anesthetics, systemic failure, malignant tumor, bacterial infection, etc; 2.Patients with autoimmune diseases such as systemic lupus erythematosus or recent use of immunosuppressive agents; 3.Patients with severe central nervous system complications; 4.Patients with obvious anxiety, depression or other diseases affecting pain perception; 5.Pregnant and lactating women; 6.Withdrawal during midway or follow-up;

Design outcomes

Primary

MeasureTime frame
visual analogue scale,VAS;TNF-a;IL-8;

Secondary

MeasureTime frame
NRS-11;PSQI;PHQ-9;SF-36;Adverse reactions;

Countries

China

Contacts

Public ContactLi Dongbai

The second hospital of Dalian Medical University

dbldoctor@outlook.com+86 411 8467 1291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026